日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors.

针对 EphA5 的抗体药物偶联物在实体瘤中的第一代和临床前评估

Staquicini Fernanda I, Tang Fenny Hf, de Oliveira Vanessa, Kim Sun-Young, Chen Ethan R, Markosian Christopher, Staquicini Daniela I, Wu Yongjian, Parsons J Kellogg, Barnhart Kirstin F, Alley Stephen C, Chen Isan, Arap Wadih, Pasqualini Renata

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

术前使用西曲伐替尼和纳武利尤单抗治疗口腔癌的抗肿瘤免疫效应:SNOW 机会窗口研究

Oliva, Marc; Chepeha, Douglas; Araujo, Daniel V; Diaz-Mejia, J Javier; Olson, Peter; Prawira, Amy; Spreafico, Anna; Bratman, Scott V; Shek, Tina; de Almeida, John; R Hansen, Aaron; Hope, Andrew; Goldstein, David; Weinreb, Ilan; Smith, Stephen; Perez-Ordoñez, Bayardo; Irish, Jonathan; Torti, Dax; Bruce, Jeffrey P; Wang, Ben X; Fortuna, Anthony; Pugh, Trevor J; Der-Torossian, Hirak; Shazer, Ronald; Attanasio, Nickolas; Au, Qingyan; Tin, Antony; Feeney, Jordan; Sethi, Himanshu; Aleshin, Alexey; Chen, Isan; Siu, Lillian

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

一项针对去势抵抗性前列腺癌的新型抗雄激素药物ARN-509的I期研究

Rathkopf, Dana E; Morris, Michael J; Fox, Josef J; Danila, Daniel C; Slovin, Susan F; Hager, Jeffrey H; Rix, Peter J; Chow Maneval, Edna; Chen, Isan; Gönen, Mithat; Fleisher, Martin; Larson, Steven M; Sawyers, Charles L; Scher, Howard I

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

舒尼替尼与干扰素α治疗转移性肾细胞癌患者的总生存期及最新结果

Motzer, Robert J; Hutson, Thomas E; Tomczak, Piotr; Michaelson, M Dror; Bukowski, Ronald M; Oudard, Stéphane; Negrier, Sylvie; Szczylik, Cezary; Pili, Roberto; Bjarnason, Georg A; Garcia-del-Muro, Xavier; Sosman, Jeffrey A; Solska, Ewa; Wilding, George; Thompson, John A; Kim, Sindy T; Chen, Isan; Huang, Xin; Figlin, Robert A

Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa

生活质量可预测接受舒尼替尼治疗的转移性肾细胞癌患者的无进展生存期(与接受干扰素α治疗的患者相比)。

Cella, David; Cappelleri, Joseph C; Bushmakin, Andrew; Charbonneau, Claudie; Li, Jim Z; Kim, Sindy T; Chen, Isan; Michaelson, M Dror; Motzer, Robert J